<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04913298</url>
  </required_header>
  <id_info>
    <org_study_id>21-0236</org_study_id>
    <nct_id>NCT04913298</nct_id>
  </id_info>
  <brief_title>Prospective Study for the Application of Cytosorb® in Critically Ill Patients</brief_title>
  <acronym>Cyto-SOLVE</acronym>
  <official_title>Prospective Quality Assurance Study for the Application of Cytosorb® in Patients With Cytokine Storm, Rhabdomyolysis and Acute Liver Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ludwig-Maximilians - University of Munich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The mortality of critically ill patients is persistently high and requires targeted therapy&#xD;
      of pathophysiological disorders. One approach to optimize therapy is the use of the cytokine&#xD;
      adsorber Cytosorb®, which has a CE certification for the indications hyperinflammation,&#xD;
      rhabdomyolysis and liver failure and is therefore frequently used in patients with sepsis,&#xD;
      polytrauma and acute liver failure. Although few clinical data describe the efficiency mostly&#xD;
      retrospectively, there are no data on real-time elimination performance and saturation&#xD;
      kinetics during the course of treatment. These questions should be answered by the present&#xD;
      study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change (percentage) in different cytokines (measured as a cytokine panel) measured pre- and post-CytoSorb® (extracorporeal) in intensive care patients with hyperinflammation</measure>
    <time_frame>12 hours</time_frame>
    <description>Measurement of a cytokine panel (20 different cytokines in one panel) before and after the filter at different times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change (percentage) in myoglobin measured pre- and post-CytoSorb® (extracorporeal) in intensive care patients with rhabdomyolysis</measure>
    <time_frame>12 hours</time_frame>
    <description>Measurement of myoglobin before and after the filter at different times.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change (percentage) in bile acids (measured as a panel) measured pre- and post-CytoSorb® (extracorporeal) in intensive care patients with acute liver failure</measure>
    <time_frame>12 hours</time_frame>
    <description>Measurement of bile acids before and after the filter at different times.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change (percentage) in norepinephrine demand before and after the use of CytoSorb®</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change ( percentage ) of liver toxic substances (e.g. bile acids) in patients´ blood due to the use of CytoSorb®</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change ( percentage ) of myoglobin in patients´ blood due to the use of CytoSorb®</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference (percentage) between predicted mortality and real mortality of patients treated with CytoSorb®</measure>
    <time_frame>2 years</time_frame>
    <description>Mortality can be predicted by intensive care scores. We will investigate the difference between actual and predicted mortality.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Rhabdomyolysis</condition>
  <condition>Acute Liver Injury</condition>
  <condition>Cytokine Storm</condition>
  <arm_group>
    <arm_group_label>Cytosorb therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>blood samples are taken before and after the cytokine adsorber at given times</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cytosorb therapy</intervention_name>
    <description>Start of Cytosorb therapy is at the discretion of the attending physician</description>
    <arm_group_label>Cytosorb therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  intensive care therapy&#xD;
&#xD;
          -  hyperinflammation or acute liver dysfunction or rhabdomyolysis&#xD;
&#xD;
          -  need of continuous renal replacement therapy&#xD;
&#xD;
          -  treatment with Cytosorb (decision of the attending physician)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - other reasons for Cytosorb application&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Christina Scharf</last_name>
    <phone>+49-89-4400-44152</phone>
    <email>christina.scharf@med.uni-muenchen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>LMU munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Scharf</last_name>
      <phone>+49-89-4400-44152</phone>
      <email>christina.scharf@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2021</study_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ludwig-Maximilians - University of Munich</investigator_affiliation>
    <investigator_full_name>Michael Zoller MD</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Cytosorb</keyword>
  <keyword>adsorption kinetics</keyword>
  <keyword>saturation</keyword>
  <keyword>critically ill patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhabdomyolysis</mesh_term>
    <mesh_term>Cytokine Release Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

